アットビア・セラピューティクス
ATTO
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
| 期間 | EPS | 売上 | FCF |
|---|---|---|---|
| 2026 Q3 | -0.49 | $0 | -$26M |
| 2026 Q2 | -0.45 | $450,000 | -$17M |
| 2026 Q1 | -0.48 | $0 | -$18M |
| 2025 Q4 | -0.38 | $990,000 | -$17M |
| 2025 Q2 | -0.56 | $0 | -$13M |
| 2025 Q1 | -0.40 | $0 | -$16M |